Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Caficrestat (Primary)
- Indications Diabetic cardiomyopathy; Diabetic neuropathies
- Focus Registrational; Therapeutic Use
- Acronyms ARISE-HF
- Sponsors Applied Therapeutics
- 19 Jul 2024 Last checked against ClinicalTrials.gov record.
- 09 May 2024 According to an Applied Therapeutics media release, full results from this study were presented at the 2024 American College of Cardiology Annual Scientific Session and published in the Journal of the American College of Cardiology (JACC).
- 04 Apr 2024 According to an Applied Therapeutics media release, full results from the study will be presented in an oral presentation at the 2024 American College of Cardiology (ACC) Annual Scientific Session to take place April 6-8, 2024 in Atlanta, Georgia.